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a b s t r a c t
SAMHD1 is a human restriction factor that prevents efﬁcient infection of macrophages, dendritic cells
and resting CD4þ T cells by HIV-1. Here we explored the antiviral activity and biochemical properties of
human SAMHD1 polymorphisms. Our studies focused on human SAMHD1 polymorphisms that were
previously identiﬁed as evolving under positive selection for rapid amino acid replacement during
primate speciation. The different human SAMHD1 polymorphisms were tested for their ability to block
HIV-1, HIV-2 and equine infectious anemia virus (EIAV). All studied SAMHD1 variants block HIV-1, HIV-2
and EIAV infection when compared to wild type. We found that these variants did not lose their ability to
oligomerize or to bind RNA. Furthermore, all tested variants were susceptible to degradation by Vpx, and
localized to the nuclear compartment. We tested the ability of human SAMHD1 polymorphisms to
decrease the dNTP cellular levels. In agreement, none of the different SAMHD1 variants lost their ability
to reduce cellular levels of dNTPs. Finally, we found that none of the tested human SAMHD1
polymorphisms affected the ability of the protein to block LINE-1 retrotransposition.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Efﬁcient infection of human primary macrophages, dendritic
cells and resting CD4þ T-cells by simian immunodeﬁciency virus
(SIVmac) requires the accessory protein Vpx (Arﬁ et al., 2008;
Baldauf et al., 2012; Descours et al., 2012; Goujon et al., 2008,
2003, 2007; Spragg and Emerman, 2013). Vpx is essential for both
SIV infection of primary macrophages and viral pathogenesis
in vivo (Belshan et al., 2006; Fletcher et al., 1996; Gibbs et al.,
1995; Hirsch et al., 1998). Vpx is incorporated into viral particles
suggesting that it might be acting immediately after viral fusion
(Jin et al., 2001; Kappes et al., 1993; Park and Sodroski, 1995; Selig
et al., 1999; Yu et al., 1988). Viral reverse transcription is prevented
in primary macrophages when cells are infected with either Vpx-
deﬁcient SIVmac or HIV-2 (Bergamaschi et al., 2009; Fujita et al.,
2008; Goujon et al., 2007; Kaushik et al., 2009; Srivastava et al.,
2008). Interestingly, Vpx also increases the ability of HIV-1 to
efﬁciently infect macrophages, dendritic cells and resting CD4þ T
cells when Vpx is incorporated into HIV-1 particles or supplied in
trans (Baldauf et al., 2012; Descours et al., 2012; Goujon et al.,
2008; Sunseri et al., 2011; Yu et al., 1991). Recent work identiﬁed
SAMHD1 as the protein that blocks infection of SIVΔVpx, HIV-
2ΔVpx and HIV-1 before reverse transcription in macrophages,
dendritic cells and resting CD4þ T cells (Baldauf et al., 2012;
Berger et al., 2011; Descours et al., 2012; Hrecka et al., 2011;
Laguette et al., 2011). Mechanistic studies have suggested that Vpx
induces the proteasomal degradation of SAMHD1 (Berger et al.,
2011; Hrecka et al., 2011; Laguette et al., 2011). In agreement, the
C-terminal region of SAMHD1 contains a Vpx binding motif, which
is important for the ability of Vpx to degrade SAMHD1 (Ahn et al.,
2012; Fregoso et al., 2013; Laguette et al., 2012; Zhang et al., 2012).
Some Vpx proteins target the N-terminal region of SAMHD1
suggesting more than one mechanism for degradation (Fregoso
et al., 2013; Wei et al., 2014). SAMHD1 is a dGTP-regulated
deoxynucleotide triphosphohydrolase (dNTPs) that decreases the
overall cellular levels of dNTPs (Goldstone et al., 2011; Kim et al.,
2012; Lahouassa et al., 2012; Powell et al., 2011).
SAMHD1 is comprised of the sterile alpha motif (SAM) and
histidine-aspartic (HD) domains. The HD domain of SAMHD1 is a
dGTP-regulated deoxynucleotide triphosphohydrolase that
decreases the cellular levels of dNTPs (Goldstone et al., 2011;
Kim et al., 2012; Lahouassa et al., 2012; Powell et al., 2011). The
sole HD domain is sufﬁcient to potently restrict infection by
different viruses (White et al., 2013a). The HD domain is also
necessary for the ability of SAMHD1 to oligomerize and to bind
RNA (White et al., 2013a). The decrease in dNTP levels in myeloid
cells correlates with the inability of lentiviruses to undergo reverse
transcription.
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Recent ﬁndings have suggested that the antiviral activity of
SAMHD1 is regulated by phosphorylation (Cribier et al., 2013;
Welbourn et al., 2013; White et al., 2013b). Interestingly, an
antivirally active SAMHD1 is unphosphorylated on T592. By con-
trast, SAMHD1 phosphorylated on T592 is antivirally inactive.
These ﬁndings showed that contrary to what happens in cycling
cells, SAMHD1 is unphosphorylated in non-cycling cells. These
results proposed an explanation for the reason that SAMHD1 is
expressed in cycling and non-cycling cells, but it only exhibits
antiviral activity in non-cycling cells.
The human population contains several SAMHD1 polymorphisms;
however, the ability of human SAMHD1 polymorphisms to block HIV-
1 infection is not known. Here we investigated the ability of the
different human SAMHD1 polymorphisms for their ability to block
HIV-1 and equine infectious anemia virus (EIAV) infection. Further-
more, we tested the different human SAMHD1 polymorphisms for
oligomerization, RNA binding, Vpx-mediated degradation, subcellular
localization, and ability to decrease the cellular levels of dNTPs.
Results
Identiﬁcation of human SAMHD1 polymorphisms
We wished to functionally assess the impact of SAMHD1 single
nucleotide polymorphisms (SNPs) circulating in the human popu-
lation. As of June 2012, there were non-synonymous SNPs reported
in 26 codon positions in SAMHD1. From these, we focused on SNPs
reported at three codon positions (408, 601, 614) that were
previously identiﬁed as evolving under positive selection for rapid
amino acid replacement during primate speciation (Fig. 1A and B)
(Laguette et al., 2012; Lim et al., 2012). We also focused on SNPs at
two codons (33, 611) where more than one human SNP has been
reported in the same codon (Fig. 1A). SNPs in codons under
positive selection, and in codons where multiple SNPs are co-
circulating, have previously been found to be functionally relevant
in restriction factor genes (Johnson and Sawyer, 2009; Meyerson
and Sawyer, 2011). This is presumably because both patterns
might arise if selection is acting to retain new variants that arise
in populations. We also aligned SAMHD1 protein sequences from
46 non-human primate species, and list the alternate amino acids
encoded at each of these positions in different primate species
(Fig. 1A). The human SNPs observed at sites 112, 408, and 611 re-
sample amino acids encoded by other primate species, another
pattern that has been observed at positions of functional signiﬁ-
cance in restriction factors (Meyerson and Sawyer, 2011)
Ability of human SAMHD1 polymorphisms to block HIV-1 infection
To evaluate the ability of human SAMHD1 polymorphisms to
block HIV-1 infection, we inserted the SNPs changes in a SAMHD1-
FLAG construct. Subsequently, we stably expressed the human
SAMHD1-FLAG polymorphisms in the human monocytic cell line
U937, as previously described (Brandariz-Nunez et al., 2012; White
et al., 2013a, 2013b). U937 stably expressing the different human
SAMHD1-FLAG polymorphisms were differentiated by treatment
with Phorbol 12-myristate 13-acetate (PMA) (Schwende et al.,
1996), and the expression level of human SAMHD1-FLAG poly-
morphisms was determined by western blotting using anti-FLAG
antibodies (Fig. 2A).
Next, we tested the ability of the different human SAMHD1
polymorphisms to restrict HIV-1 infection. For this purpose, we
challenged PMA-treated U937 cells expressing the different
SAMHD1 variants using an HIV-1 virus expressing GFP as a
reporter of infection (HIV-1-GFP). Interestingly, all tested human
SAMHD1 polymorphisms showed potent restriction of HIV-1
(Fig. 2B and Table 1). As a control, we challenged cells expressing
the SAMHD1-HD206AA variant, which does not block HIV-1
infection, by using increasing amounts of HIV-1-GFP (Hrecka et
al., 2011; Laguette et al., 2011). Similar experiments were per-
formed using an HIV-2 virus expressing GFP as a reporter of
infection (HIV-2-GFP) (Fig. 2C). These results indicated that human
SAMHD1 polymorphisms do not change the ability of SAMHD1 to
block HIV-1 or HIV-2 infection.
Ability of human SAMHD1 polymorphisms to block equine infectious
anemia virus (EIAV) infection
SAMHD1 has the ability to block EIAV infection to a less extent
when compared to HIV-1 (White et al., 2013a); therefore, we
Fig. 1. Human SAMHD1 SNPs tested in this study. (A) The tested SNPs are listed. Some of these SNPs (408, 601, 614) fall in codons that have previously been identiﬁed as
evolving under positive selection for rapid amino acid change during primate speciation (Laguette et al., 2012; Lim et al., 2012). Two codon positions (33 and 611) each bear
two unique SNPs reported in the human population. The two SNPs at position 33 are different in that one is a nucleotide change affecting the ﬁrst position of the codon, and
the other is a change affecting the second position of the codon. In the case of 611, both SNPs are reported to affect the second position of the codon, although validation is
uncertain for one of these SNPs (R611L). An alignment of SAMHD1 protein sequences from 46 non-human primate species was used to determine the amino acids encoded at
these positions by non-human primates. Notes address the source of each SNP reported. NHLBI-ESP stands for “National Heart, Lung, and Blood Institute Exome Sequencing
Project”. (B) A domain diagram of SAMHD1 shows the SAM and HD domains. Purple balls indicate the position of the SNPs in panel A, which were tested in this study. As a
reference green balls indicate amino acid positions where non-synonymous point mutations are linked to Aicardi–Goutières syndrome (Rice et al., 2009).
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Fig. 2. Ability of human SAMHD1 polymorphisms to restrict HIV-1 infection. PMA-treated human monocytic U937 cells stably expressing the indicated human SAMHD1
polymorphisms (A) were challenged with increasing amounts of HIV-1-GFP (B) or HIV-2-GFP (C). As a control, U937 cells stably transduced with the empty vector LPCX were
challenged with HIV-1-GFP. Similar results were obtained in three independent experiments and a representative experiment is shown. WT, wild type.
T.E. White et al. / Virology 460-461 (2014) 34–4436
Table 1
Human SAMHD1 polymorphisms.
SAMHD1
variant
HIV-1
restrictiona
EIAV
restrictionb
Oligomerizationc RNA
bindingd
Vpx
degradatione
Localizationf Cellular dATP
levelg
LINE-1
retrotranspositionh
WT þ þ þ þ þ N Low No
S33A þ þ þ þ þ N Low ND
S33Y þ þ þ þ þ N Low No
V112I þ þ þ þ þ N Low No
R408H þ þ þ þ þ N Low No
S601C þ þ þ þ þ N Low No
R611L þ þ þ þ þ N Low No
R611Q þ þ þ þ þ N Low No
S614F þ þ þ þ þ N Low No
WT, wild type; ND, not determined.
a,b Restriction was measured by infecting cells expressing the indicated human SAMHD1 polymorphism with HIV-1-GFP or EIAV-GFP. After 48 h, the percentage of GFP-
positive cells (infected cells) was determined by ﬂow cytometry. “þ” Indicates inhibition of infection similar to the one imposed by wild type SAMHD1.
c Human SAMHD1-FLAG polymorphisms were assayed for association with wild-type SAMHD1-HA as described in the section “Materials and methods”. “þ” Indicates
similar oligomerization to the one observed for wild-type SAMHD1.
d Human SAMHD1-FLAG polymorphisms were assayed for RNA binding as described in the section “Materials and methods”. “þ” Indicates similar RNA binding to the
one observed for wild type SAMHD1.
e Vpx-dependent degradation of each human SAMHD1 polymorphism was determined as described in the section “Materials and methods”. “þ” Indicates similar Vpx-
mediated SAMHD1 degradation to the one observed for wild type SAMHD1.
f The subcellular localization of human SAMHD1 polymorphisms was determined as described in the section “Materials and methods”. For each experiment, 200 cells
were counted. “N” indicates nuclear localization.
g The cellular dATP levels of U937 cells stably expressing the different human SAMHD1 polymorphisms were determined as described in the section “Materials and
Methods”. “Low” indicates similar dATP levels to the one observed for U937 cells stably expressing wild type SAMHD1.
h The ability of LINE-1 to retrotranspose was measured using an EGFP-based reporter assay as described in the section “Materials and methods”. “No” indicates that
retrotransposition has not occurred in the presence of the indicated SAMHD1 variant.
Fig. 3. Ability of human SAMHD1 polymorphisms to restrict equine infectious anemia virus (EIAV) infection PMA-treated Human monocytic U937 cells stably expressing the
indicated mutant and wild type SAMHD1 proteins were challenged with increasing amounts of EIAV-GFP. As a control, U937 cells stably transduced with the empty vector
LPCX were challenged with EIAV-GFP. Similar results were obtained in three independent experiments and a representative experiment is shown.
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decided to test the ability of human SAMHD1 polymorphisms to
block EIAV-GFP infection. Because the ability of SAMHD1 to block
EIAV-GFP is less potent when compared to HIV-1 (White et al.,
2013a), the goal of these experiments is to investigate whether
these polymorphisms exhibit more subtle changes in restriction.
Similarly, PMA-treated U937 cells expressing the different human
SAMHD1-FLAG polymorphisms were challenged with increasing
amounts of EIAV-GFP, as described (Diaz-Griffero et al., 2008). As
shown in Fig. 3, all tested human SAMHD1 polymorphisms
blocked the infection ability of EIAV-GFP. As a control, we
challenged cells expressing the SAMHD1-HD206AA variant, which
does not block HIV-1 infection (Hrecka et al., 2011; Laguette et al.,
2011), by using increasing amounts of EIAV-GFP. These results are
in agreement with the hypothesis that human SAMHD1 poly-
morphisms are not affected in their ability to block HIV-1
infection.
Oligomerization of human SAMHD1 polymorphisms
We have previously demonstrated the ability of SAMHD1 to
oligomerize in mammalian cells (White et al., 2013a), which is in
agreement with biochemical data suggesting that SAMHD1 is a
tetramer (Brandariz-Nunez et al., 2013; Goldstone et al., 2011; Ji et
al., 2013; Yan et al., 2013; Zhu et al., 2013). For this purpose, we
tested the ability of the different human SAMHD1-FLAG poly-
morphisms to oligomerize with wild type SAMHD1-HA. As shown
in Fig. 4, all the tested human SAMHD1 polymorphisms were
intact for their ability to form oligomers. As a control, we tested
the oligomerization ability of the SAMHD1-Y146S/Y154S variant,
which is defective for oligomerization (Brandariz-Nunez et al.,
2013). These results indicated that all tested human SAMHD1
polymorphisms are not defective for oligomerization.
Capability of human SAMHD1 polymorphisms to bind RNA
We and others have demonstrated the ability of SAMHD1 to
bind RNA (Goncalves et al., 2012; White et al., 2013b). Next we
tested the ability of human SAMHD1 polymorphisms to bind the
interferon-stimulatory DNA sequence containing a phosphorothio-
ate backbone (ISD-PS), which is an RNA analog. As a control, we
tested the ability of the SAMHD1 deletion construct 1–150, which
is defective on its ability to bind RNA (White et al., 2013a). As
shown in Fig. 5, all tested human SAMHD1 polymorphisms
interacted with ISD-PS when compared to wild-type SAMHD1.
Ability of Vpx to degrade human SAMHD1 polymorphisms
Because the viral protein Vpx from different viruses induces the
degradation of SAMHD1, we tested the ability of Vpx from HIV-
2ROD (VpxROD) to degrade the different human SAMHD1 poly-
morphisms, as previously described (White et al., 2013b). For this
purpose, we cotransfected the different human SAMHD1 poly-
morphisms together with VpxROD and measure the expression
level of SAMHD1 (Fig. 6). As a control, we cotransfected the
different human SAMHD1 polymorphisms with Vpx SIVrcm
(Vpxrcm), which is unable to induce the degradation of human
SAMHD1 (Brandariz-Nunez et al., 2012). As shown in Fig. 6, all the
tested human SAMHD1 polymorphisms were degraded by VpxROD
(Table 1). These results indicated that human SAMHD1 poly-
morphisms are not defective in their ability to be degraded by Vpx.
Subcellular localization of human SAMHD1 polymorphisms
SAMHD1 is a nuclear protein that exhibits a nuclear localization
signal on residues 11KRPR14 (Brandariz-Nunez et al., 2012;
Hofmann et al., 2012; Rice et al., 2009; Wei et al., 2012). Next
we tested the subcellular localization of human SAMHD1 poly-
morphisms in HeLa cells by immunoﬂuorescence, as previously
described (Brandariz-Nunez et al., 2012). For this purpose, we
transiently transfected the different human SAMHD1-FLAG poly-
morphisms in HeLa cells and performed immunoﬂuorescence
staining using anti-FLAG antibodies. As control, we stained the
cellular nuclei using DAPI. As shown in Fig. 7, all tested human
SAMHD1 polymorphisms localized to the nucleus (Table 1). These
experiments suggested that the different human SAMHD1 poly-
morphisms are not affected for their ability to localize in the
nuclear compartment.
Level of cellular dNTPs in U937 cells stably expressing the different
human SAMHD1 polymorphisms
Previous observations have suggested that SAMHD1 decreases
the intracellular pool of deoxynucleotide triphosphates (dNTPs)
Fig. 4. Oligomerization of the different human SAMHD1 polymorphisms. Human 293FT cells were cotransfected with a plasmid expressing wild type SAMHD1-HA with
either plasmids expressing wild type or the indicated SAMHD1-FLAG variant. Cells were lysed 24 h after transfection and analyzed by Western blotting using anti-HA and
anti-FLAG antibodies (Input). Subsequently, lysates were immunoprecipitated by using anti-FLAG agarose beads, as described in the section “Materials and methods”. Anti-
FLAG agarose beads were eluted using FLAG peptide, and elutions were analyzed by Western blotting using anti-HA and anti-FLAG antibodies (IP). Similar results were
obtained in three independent experiments and representative data is shown. WB, Western blot; IP, immunoprecipitation; WT, wild type.
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(Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al., 2012;
Powell et al., 2011; White et al., 2013a). To test whether the
different human SAMHD1 proteins are affected on their ability to
decrease the cellular levels of dNTPs, we measured the levels of
dATP, dTTP and dGTP in U937 cells stably expressing the different
human SAMHD1 polymorphisms. As shown in Fig. 8, all tested
human SAMHD1 polymorphisms were able to decrease the cel-
lular levels of dNTPs.
Ability of human SAMHD1 polymorphisms to modulate LINE-1
retrotransposition
Previous investigations have reported the ability of SAMHD1 to
negatively modulate retrotransposition of the long interspersed
element 1 (LINE-1) (Zhao et al., 2013). Here we tested the ability of
the different human SAMHD1 polymorphisms to negatively mod-
ulate the LINE-1 retrotransposition. For this purpose, we used a
reporter assay to measure LINE-1 retrotransposition in human
Fig. 5. Human SAMHD1 polymorphisms binding to nucleic acids. Human 293T cells were transfected with plasmid expressing the indicated Human SAMHD1
polymorphisms. Lysed cells 24 h after transfection (Input) were incubated with ISD-PS immobilized in StrepTactin Superﬂow afﬁnity resin. Similarly, eluted proteins from
the resin were visualized by Western blotting using anti-FLAG antibodies (BOUND). Similar results were obtained in three independent experiments and a representative
experiment is shown. ISD-PS, interferon-stimulatory DNA sequence containing a phosphorothioate backbone; WB, Western blot; WT, wild type.
Fig. 6. Vpx-dependent degradation of single nucleotide polymorphisms of SAMHD1. HeLa cells were cotransfected with plasmids expressing the indicated SAMHD1 variants
and HA-tagged Vpx from HIV-2ROD (VpxROD) or SIVRCM (Vpxrcm). Thirty-six hours post-transfection cells were harvested, and the expression levels of SAMHD1 and Vpx were
analyzed by Western blotting using anti-FLAG and anti-HA antibodies. As a loading control, cell extracts were Western blotted using antibodies against GAPDH. Similar
results were obtained in three independent experiments and a representative experiment is shown. SAMHD1 degradation is expressed as percentage of remaining SAMHD1
protein (lower panels), and a standard deviation is shown.
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HEK293T cells (Goodier et al., 2013). We used the LINE-1 construct
99-PUR-RPS-EGFP (L1RP-EGFP), which contains an EGFP reporter
gene interrupted by an intron in the opposite transcriptional
orientation (Fig. 9A). The EGFP cassette is inserted into the 30UTR
of a retrotransposition-component L1 (L1RP). EGFP is expressed
only when the intron of the LINE-1 transcript is removed by
splicing, and the resulting transcript is reverse transcribed and
subsequently integrated into the genomic DNA. After integration
the EGFP gene will be expressed from its CMV promoter (Fig. 9A).
As a control, we will use the same L1RP EGFP construct containing
Fig. 7. Intracellular distribution of human SAMHD1 polymorphisms in HeLa cells.
HeLa cells expressing the indicated human SAMHD1 polymorphism were ﬁxed and
immunostained using antibodies against FLAG (red). Cellular nuclei were stained by
using DAPI (blue). Similar results were obtained in three independent experiments
and a representative experiment is shown. WT, wild type.
Fig. 8. Cellular dATP, dTTP and dGTP levels in U937 cells stably expressing the
different human SAMHD1 polymorphisms. Quantiﬁcation of dATP, dTTP and dGTP
levels on PMA-treated U937 cells expressing the indicated human SAMHD1
polymorphism was performed by a primer extension assay as described in the
section “Materials and methods”. Similar results were obtained in three indepen-
dent experiments and standard deviation is shown. WT, wild type.
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two missense mutations on the ORF1 (JM111) (Fig. 9A) (Moran et
al., 1996). As shown in Fig. 9B, all tested SAMHD1 polymorphisms
negatively modulated LINE-1 retrotransposition when compared
to wild type SAMHD1. As control, we used the SAMHD1 variant
H123P, which does not inhibit LINE-1 retrotransposition (Zhao et
al., 2013). These results indicated that all the tested SAMHD1
polymorphisms negatively modulated LINE-1 retrotransposition.
Discussion
This work explores the different features of human SAMHD1
polymorphisms. We have focused our experiments on studying
human polymorphisms on residues that have been positively
selected during primate speciation (Laguette et al., 2012; Lim et
al., 2012). We initially tested for the ability of these polymorph-
isms to block HIV-1 and HIV-2 infection. None of the tested
SAMHD1 polymorphisms lost the ability to block HIV-1 or HIV-2
infection. To further understand the anti-viral activity of these
variants, we tested for their ability to block EIAV, a virus restricted
by SAMHD1 to a lesser extent when compared to HIV-1. Interest-
ingly, we found that all tested SAMHD1 polymorphisms block EIAV
infection. Overall these results suggested that all tested human
SAMHD1 polymorphisms are not affected for their anti-retroviral
properties. One caveat of these experiments is that we are over-
expressing the different SAMHD1 variants, which raises the
possibility that at endogenous levels this protein might have
different anti-retroviral properties.
Next we thoroughly characterize the biochemical properties of
the different SAMHD1 polymorphisms. As we have previously
described, we have established an assay to detect oligomerization
of SAMHD1 proteins in mammalian cells (Brandariz-Nunez et al.,
2013; White et al., 2013a, 2013b). Our results indicated that all
human SAMHD1 polymorphisms retained their oligomerization
properties. Because SAMHD1 has the ability to bind RNA in vitro
(Goncalves et al., 2012; White et al., 2013a), we tested the ability of
SAMHD1 variants to bind RNA. All tested human SAMHD1 poly-
morphisms retained the ability to bind RNA in vitro.
Because Vpx triggers the degradation of SAMHD1 (Hrecka et al.,
2011; Laguette et al., 2011), we tested the ability of Vpx to induce
the degradation of the different human SAMHD1 polymorphisms.
All tested human SAMHD1 polymorphisms were degraded by Vpx.
Similarly we tested the nuclear localization of the different human
SAMHD1 variants. In agreement with our body of work, none of
the studied human SAMHD1 variants lost nuclear localization.
We and others have previously reported that the ability of
SAMHD1 to decrease the cellular levels of dNTPs is necessary but
not sufﬁcient to restrict HIV-1 (Cribier et al., 2013; Welbourn et al.,
2013; White et al., 2013b). If these functions were independent,
SAMHD1 polymorphisms where the ability to decrease the cellular
levels of dNTPs is lost were expected to emerge. However, we did
not observe these in the studied polymorphisms. The fact that we
did not ﬁnd SAMHD1 polymorphisms that are affected in dNTPase
activity but not on HIV-1 restriction is in agreement with our
hypothesis that dNTPase activity is necessary but not sufﬁcient for
restriction.
We also tested the ability of the different SAMHD1 variants to
decrease the cellular levels of dNTPs. None of the tested human
SAMHD1 polymorphisms decreased the cellular levels of dNTPs.
Finally, we tested the ability of the different human SAMHD1
polymorphisms to negatively modulate LINE-1 retrotransposition.
In agreement with previous ﬁndings suggesting that SAMHD1
negatively modulate LINE-1 retrotransposition (Zhao et al., 2013),
we found that all tested human SAMHD1 polymorphisms negatively
modulate LINE-1 retrotransposition. Overall our work demonstrated
that all the human SAMHD1 polymorphisms studied here did not
show any defect on antiviral activity, oligomerization, binding to
RNA, Vpx-mediated degradation, subcellular localization, dNTPase
activity, and inhibition of LINE-1 retrotransposition.
Materials and methods
Identiﬁcation of human SNPs
SNPs were identiﬁed in the dbSNP database at NCBI (http://
www.ncbi.nlm.nih.gov/SNP/), and cross-checked against data in
the 1000 Genomes project (http://www.1000genomes.org/).
S601C was observed only one time, in the genome of an Asian
individual. R611Q was observed one time in an African individual,
and one time in an individual from the Americas. Except for these
two SNPs, both included in the 1000 Genomes project, information
on the geographic distribution of other SNPs is unknown. Efforts to
obtain further information regarding the source of the R611L SNP
Fig. 9. Modulation of LINE-1 retrotransposition by human SAMHD1 SNPs. (A)
Schematic representation of the different vectors used in the LINE-1 enhanced-GFP
(EGFP)-based reporter assay. LINE-1, 99-PUR-RPS-EGFP (L1RP-EGFP) and JM111
(JM111) are shown. The 99-PUR-RPS-EGFP contains combined promoters from
both CMV and the 50-UTR of the LINE-1. An antisense cassette of EGFP containing
an inserted intron sequence was cloned near the 30 end of the L1 30 UTR. JM111, the
negative control for retrotransposition, contains the double mutation R261A/R262A
in ORF1, which has been shown to abolish the retrotransposition activity of LINE-1.
The occurrence of retrotransposition is detected by expression of EGFP in human
HEK293T cells. (B) The ability of the indicated SAMHD1 variants to inhibit retro-
transposition was measured by cotransfecting the LINE-1 reporter vector, 99 PUR
RPS EGFP (L1RP-EGFP), together with the different FLAG-tagged SAMHD1 variants
into HEK293T cells. Five days post-transfection, the occurrence of retrotransposi-
tion was determined by expression of EGFP measured by ﬂow cytometry. As
control, we have cotransfected the empty vector LPCX in HEK 293T cells as
described in the section “Materials and methods”. The defective LINE-1 construct,
JM111, was used for determining the background levels of EGFP. The SAMHD1
mutant H123P was used as a positive control. Experiments were performed in
triplicates and a standard deviation is shown.
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record at NCBI were not fruitful. Non-human primate SAMHD1
sequences were downloaded from Genbank.
Cell lines and plasmids
Human U937 (ATCC#CRL-1593) cells were grown in RPMI
supplemented with 10% (v/v) fetal bovine serum and 1% (v/v)
penicillin/streptomycin. Human HeLa cells (ATCC#CCL-2) were
grown on DMEM supplemented with 10% fetal bovine serum
and 1% (w/v) penicillin/streptomycin. LPCX-SAMHD1-FLAG plas-
mids expressing the codon optimized SAMHD1 fused to either
FLAG epitope were previously described (Brandariz-Nunez et al.,
2012). The plasmids expressing human SAMHD1 polymorphisms
were created using speciﬁc primers and pLPCX-SAMHD1-FLAG as
template.
Generation of U937 cells stably expressing SAMHD1 variants
Retroviral vectors encoding wild type or mutant SAMHD1
proteins fused to FLAG were created using the LPCX vector
(Clontech). Recombinant viruses were produced in 293T cells by
co-transfecting the LPCX plasmids with the pVPack-GP and
pVPack-VSV-G packaging plasmids (Clontech). The pVPack-VSV-G
plasmid encodes the vesicular stomatitis virus G envelope glyco-
protein, which allows efﬁcient entry into a wide range of verte-
brate cells (Yee et al., 1994). Transduced human monocytic U937
cells were selected in 0.4 μg/ml puromycin (Sigma).
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer as previously described (Lienlaf et al.,
2011). Detection of proteins by Western blotting was performed
using anti-FLAG (Sigma) or anti-GAPDH (Ambion) antibodies.
Secondary antibodies against rabbit and mouse conjugated to
Alexa Fluor 680 were obtained from Li-Cor. Bands were detected
by scanning blots using the Li-Cor Odyssey Imaging System in the
700 nm channel.
Infection with retroviruses expressing the green ﬂuorescent protein
(GFP)
Recombinant retroviruses expressing GFP, pseudotyped with
the VSV-G glycoprotein, were prepared as described (Diaz-Griffero
et al., 2008). For infections, 6104 cells were seeded in 24-well
plates and treated with 10 ng/ml phorbol-12-myristate-3-acetate
(PMA) for 16 h. PMA stock solution was prepared in DMSO at
250 mg/ml. Subsequently, cells were incubated with the indicated
retrovirus for 48 h at 37 1C. The percentage of GFP-positive cells
was determined by ﬂow cytometry (Becton Dickinson). Viral
stocks were titrated by serial dilution on dog Cf2Th cells.
SAMHD1 oligomerization assay
Approximately 1.0107 human 293T cells were cotransfected
with plasmids encoding SAMHD1 variants tagged with FLAG and
HA. After 24 h, cells were lysed in 0.5 ml of whole-cell extract
(WCE) buffer (50 mM Tris [pH 8.0], 280 mM NaCl, 0.5% IGEPAL, 10%
glycerol, 5 mM MgCl2, 50 μg/ml ethidium bromide, 50 U/ml ben-
zonase [Roche]). Lysates were centrifuged at 14,000 rpm for 1 h
at 4 1C. Post-spin lysates were then pre-cleared using protein
A-agarose (Sigma) for 1 h at 4 1C; a small aliquot of each of these
lysates was stored as Input. Pre-cleared lysates containing the tagged
proteins were incubated with anti-FLAG-agarose beads (Sigma) for 2 h
at 4 1C. Anti-FLAG-agarose beads were washed three times in WCE
buffer, and immune complexes were eluted using 200 μg of FLAG
tripeptide/ml in WCE buffer. The eluted samples were separated by
SDS–PAGE and analyzed by Western blotting using either anti-HA or
anti-FLAG antibodies (immunoprecipitates).
Nucleic-acid binding assay
Nucleic-acid binding assay was performed as previously
described (Goncalves et al., 2012; White et al., 2013a). In brief,
the synthetic DNA phosphorothioate-containing interferon-stimu-
latory DNA (ISD-PS), which is an RNA analog, was synthesized
with a 50-biotin tag using the following primers: ISD sense 50-
tacagatctactagtgatctatgactgatctgtacatgatctaca-30, and ISD anti-
sense 50-tgtagatcatgtacagatcagtcatagatcactagtagatctgta-30.
Sense and antisense primers were incubated at 65 1C for
20 min, and primers were allowed to anneal by cooling down to
room temperature. Annealed primers were immobilized on an
Ultralink Immobilized Streptavidin Plus Gel (Pierce). Cells were
lysed using TAP lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 5%
glycerol, 0.2% NP-40, 1.5 mM MgCl2, 25 mM NaF, 1 mM Na3VO4,
protease inhibitors) and lysates were cleared by centrifugation.
Cleared lysates (Input) were incubated with immobilized nucleic
acids at 4 1C on a rotary wheel for 2 h in the presence of 10 μg/ml
of Calf-thymus DNA (Sigma) as a competitor. Unbound proteins
were removed by three consecutive washes in TAP lysis buffer.
Bound proteins to nucleic acids (Bound) were eluted by boiling
samples in Laemmli sample buffer (63 mM Tris–HCl, 10% glycerol
2% SDS, 0.0025% bromophenol blue) and analyzed by Western
blotting using anti-FLAG antibodies (Sigma).
Assay to measure SAMHD1 degradation by Vpx
8.0106 HeLa cells were transfected in suspension using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. Transfection mixtures contained 0.25 μg of a plasmid
expressing each human SAMHD1-FLAG polymorphism and 20 μg
of plasmids expressing either VpxROD-HA or Vpxrcm-HA. The
transfection mixture was plated in a 10 cm plate for 24 h. Subse-
quently, cells were incubated in complete media [DMEM supple-
mented with 10% fetal bovine serum and 1% (w/v) penicillin/
streptomycin] for an additional 24 h. Cells lysates were analyzed
for expression of SAMHD1-FLAG and Vpx-HA by Western blotting
using anti-FLAG and anti-HA antibodies.
Transfections and subcellular localization by immunoﬂuorescence
microscopy
Transfections of cell monolayers were performed using Lipo-
fectamine Plus reagent (Invitrogen), according to the manufac-
turer's instructions. Transfections were incubated at 37 1C for 24 h.
Indirect immunoﬂuorescence microscopy was performed as pre-
viously described (Diaz-Griffero et al., 2002). Transfected mono-
layers grown on coverslips were washed twice with PBS1X (NaCl
137 mM, KCl 2.7 mM, Na2HPO4 2H2O 10 mM, KH2PO4 mM) and
ﬁxed for 15 min in 3.9% paraformaldehyde in PBS1X. Fixed cells
were washed twice in PBS1X, permeabilize for 4 min in permea-
bilizing buffer (0.5% Triton X-100 in PBS), and then blocked in
PBS1X containing 2% bovine serum albumin (blocking buffer) for
1 h at room temperature. Cells were then incubated for 1 h at
room temperature with primary antibodies diluted in blocking buffer.
After three washes with PBS, cells were incubated for 30 min in
secondary antibodies and 1 μg of 49,69-diamidino-2-phenylindole
(DAPI)/ml. Samples were mounted for ﬂuorescence microscopy by
using the ProLong Antifade Kit (Molecular Probes, Eugene, OR).
Images were obtained with a Zeiss Observer.Z1 microscope using a
63 objective, and deconvolutionwas performed using the software
AxioVision V4.8.1.0 (Carl Zeiss Imaging Solutions).
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Cellular dNTPs quantiﬁcation by a primer extension assay
2–3106 cells were collected for each cell type. Cells were
washed twice with 1 PBS, pelleted and resuspended in ice cold
65% methanol in Millipore grade water. Cells were vortexed for
2 min and incubated at 95 1C for 3 min. Cells were centrifuged at
14,000 rpm for 3 min and the supernatant was transferred to a
new tube for the complete drying of the methanol by using a
speed vac. The dried samples were resuspended in Millipore grade
water. An 18-nucleotide primer labeled at the 50 end with a-32P
(50-GTCCCTGTTCGGGCGCCA-30) was annealed at a 1:2 ratio
respectively to four different 19-nucleotide templates (50-
NTGGCGCCCGAACAGGGAC-30), where “N” represents nucleotide
variation at the 50 end. Reaction condition contains 200 fmoles of
template primer, 2 μl of 0.5 mM dNTP mix for positive control or
dNTP cell extract, 4 μl of excess HIV-1 RT, 25 mM Tris–HCl, pH 8.0,
2 mM dithiothreitol, 100 mM KCl, 5 mM MgCl2, and 10 μM oligo
(dT) to a ﬁnal volume of 20 μl. The reaction was incubated at 37 1C
for 5 min before being quenched with 10 μl of 40 mM EDTA and
99% (v/v) formamide at 95 1C for 5 min. The extended primer
products were resolved on a 14% urea–PAGE gel and analyze using
a phosphoimager. The extended products were quantiﬁed using
QuantityOne software to quantify percent volume of saturation.
The quantiﬁed dNTP content of each sample was accounted for
based on its dilution factor, so that each sample volume was
adjusted to obtain a signal within the linear range of the assay
(Kim et al., 2012; Lahouassa et al., 2012).
LINE-1 retrotransposition assay
2.5105 293T cells/well were seeded in 6-well plates. The
following day, 1.0 mg of 99-PUR-RPS-EGFP(L1RP-EGFP) was co-
transfected with 0.5 mg of empty vector (LPCX) or SAMHD1
variant (three replicate wells). Five days post-transfection, cells
having a retrotransposition event, and hence expressing EGFP,
were assayed by ﬂow cytometry. Gating exclusions were based on
background ﬂuorescence of plasmid 99-PUR-JM111-EGFP(JM111),
which has a double-point mutation in ORF1 that abolishes retro-
transposition (R261A/R262A). Within each experiment, results
were normalized to ﬂuorescence of 99-PUR-RPS-EGFP co-
transfected with LPCX empty vector.
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